Abstract: The described technology may include treatment processes to increase the red blood cell (RBC) population of individuals, particularly chronic kidney disease (CKD) patients with renal anemia, by reducing an amount of Piezo1 chemical agonists in the blood of patients. In one embodiment, a method of treating a patient with renal anemia may include increasing RBC lifespan of an RBC population of the patient via reduction of a Piezo1 channel activation duration of at least a portion of the RBC population by reducing an amount of a target uremic compound in the blood of the patient, the target uremic compound having a form that prolongs the Piezo1 channel activation duration, wherein the amount of the target uremic compound may be reduced via selectively removing at least a portion of the target uremic compound from the blood of the patient. Other embodiments are described.